The science doesn't change very quickly. You can get a good overview from company news releases. Big issues that I can remember coming up were infection risk from JAK inhibition, whether the YMI candidate has some special anti-anemia property and the whole issue of Dr Tefferi's hostility to Jakafi. Those issues remain more-or-less unresolved. We know little about the deep pipeline.
I' not a bad marker for interesting topics, because I try to stay out of the day-trading discussions. but get into most of the rest.